Lunai Bioworks Inc. (LNAI) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US29350E2037

Price
0.16 USD
Market cap
829,677.69 USD
P/E (2026)
–
P/S (2026)
15.96
Dividend yield
0.00 %
Net margin
-6,851.98 %
Return on equity (ROE)
39.47 %
Return on assets (ROA)
-35.83 %

Lunai Bioworks Inc. financials

Fiscal year20252026
Revenue–51,992.00 USD
Operating income-188.97 m USD-8.70 m USD
EBIT-177.28 m USD-3.33 m USD
Net income-178.01 m USD-3.56 m USD
Diluted EPS – continuing operations-1.08 USD-1.06 USD

Full history since 2011, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Lunai Bioworks Inc.

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.